Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XLRN
Previous Symbol
CUSIPN/A
Phone617-649-9200
Debt
Debt-to-Equity RatioN/A
Current Ratio21.68
Quick Ratio21.68
Price-To-Earnings
Trailing P/E Ratio-19.49
Forward P/E Ratio-20.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.48 million
Price / Sales178.97
Cash FlowN/A
Price / CashN/A
Book Value$6.91 per share
Price / Book7.56
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-807.36%
Return on Equity-32.69%
Return on Assets-30.94%
Miscellaneous
Employees139
Outstanding Shares46,190,000
Market Cap$2.41 billion
OptionableOptionable
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.03. The biopharmaceutical company earned $3.30 million during the quarter, compared to analysts' expectations of $4.37 million. Acceleron Pharma had a negative return on equity of 32.69% and a negative net margin of 807.36%. Acceleron Pharma's revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.65) earnings per share. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
13 equities research analysts have issued twelve-month price objectives for Acceleron Pharma's shares. Their predictions range from $33.00 to $75.00. On average, they expect Acceleron Pharma's stock price to reach $56.30 in the next year. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.
What is the consensus analysts' recommendation for Acceleron Pharma?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.
What are Wall Street analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
- 1. Cann analysts commented, "Loss per share was $0.63 compared to our estimated loss of $0.57. The slightly higher than estimated loss was the result of R&D expenses of $24.7 million being 14.6% higher than our estimated $21.5 million. This was partially offset by higher estimated collaboration revenue and higher interest income. There were no other remarkable variances in the quarter. Our outlook for revenue remains basically unchanged. We are making modest adjustments to operating expenses, by increasing estimated R&D expense by nearly 10% per year in 2018-2022." (10/31/2018)
- 2. HC Wainwright analysts commented, "We are lowering our price target to $73, from $74, due to our lower YE18 cash estimate. The price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate to arrive at our price target." (8/3/2018)
Has Acceleron Pharma been receiving favorable news coverage?
Media headlines about XLRN stock have trended very positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acceleron Pharma earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP) and Denali Therapeutics (DNLI).
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
- Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 62)
- Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 58)
- Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 47)
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (9.41%), Janus Henderson Group PLC (3.02%), Artal Group S.A. (2.16%), Eagle Asset Management Inc. (1.91%) and Brown Advisory Inc. (1.15%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.
Which major investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., AXA, Baker BROS. Advisors LP, Pictet Asset Management Ltd., Prudential Financial Inc., Foresite Capital Management III LLC, Foresite Capital Management II LLC and DekaBank Deutsche Girozentrale. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.
Which major investors are buying Acceleron Pharma stock?
XLRN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, BlackRock Inc., Stanley Laman Group Ltd., EAM Investors LLC, First Trust Advisors LP, Putnam Investments LLC and Candriam Luxembourg S.C.A.. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $52.23.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $2.41 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.
What is Acceleron Pharma's official website?
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
